TruSpine Technolgs. - Funding Loan and Directorate Change
Announcement provided by
TruSpine Technologies Plc · TSP28/02/2023 07:00
28 February 2023
TruSpine Technologies plc
("TruSpine" or the "Company")
Funding Loan and Directorate Change
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that it has entered into a
Loan Agreement
Pursuant to the Loan Agreement, the Company received
The Funding Loan bears an interest rate of 12 per cent. per annum starting from the date on which the funds were received by the Company and ending upon full repayment of the Funding Loan with accrued interest. Should the Funding Loan not be re-paid by 31 July 2023, the interest rate will adjust to 20 per cent. per annum.
On repayment of the Funding Loan, the Company will issue a warrant over 8,000,000 new ordinary shares in the Company with an exercise price of
Directorate Change
The Company also announces that Ian Roberts has resigned from his role as a director (Chief Executive Officer) of the Company with immediate effect, but will continue as an employee of the Company.
Appointment of acting Managing Director
Laurence Strauss has been appointed as acting Managing Director (non-board appointment). Mr. Strauss started his career in 1986 working in the City and built a private client broking business. He left the City in 1992, serving as a director of an electrical contracting business and overseeing its expansion, following which he replicated the growth model in another business. More recently, Mr. Strauss has been advising private clients on equity investments and initial public offerings.
This announcement contains inside information for the purposes of the
Enquiries:
TruSpine Technologies Plc |
Tel: +44 (0)20 3638 5025 |
Laurence Strauss, acting Managing Director |
|
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
Liam Murray / Ludovico Lazzaretti |
|
Oberon Capital (Joint Broker) |
|
Mike Seabrook / Chris Crawford
|
|
Peterhouse Capital Limited (Joint Broker & Financial Adviser) |
|
Lucy Williams / Duncan Vasey
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001 |
Anna Dunphy |
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.